Cargando…

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma

Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk of COVID-19–related mortality and exhibit variable serologic response to the vaccine. The capacity of vaccine-induced antibodie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nooka, Ajay K., Shanmugasundaram, Uma, Cheedarla, Narayana, Verkerke, Hans, Edara, Venkata V., Valanparambil, Rajesh, Kaufman, Jonathan L., Hofmeister, Craig C., Joseph, Nisha S., Lonial, Sagar, Azeem, Maryam, Manalo, Julia, Switchenko, Jeffrey M., Chang, Andres, Linderman, Susanne L., Roback, John D., Dhodapkar, Kavita M., Ahmed, Rafi, Suthar, Mehul S., Neish, Andrew S., Dhodapkar, Madhav V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2022
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462534/ https://www.ncbi.nlm.nih.gov/pubmed/35259002 http://dx.doi.org/10.1200/JCO.21.02257

Ejemplares similares

Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity
por: Moreno, Alberto, et al.
Publicado: (2023)

Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience
por: Maples, Kathryn T., et al.
Publicado: (2023)

Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?
por: Dhodapkar, Madhav V., et al.
Publicado: (2019)

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy
por: Robinson, M. Hope, et al.
Publicado: (2023)

Poster: CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
por: Chang, Andres, et al.
Publicado: (2022)

CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
por: Chang, Andres, et al.
Publicado: (2022)

Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention
por: McCachren, Samuel S., et al.
Publicado: (2021)

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
por: Gu, Yanyan, et al.
Publicado: (2020)

Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells
por: Dhodapkar, Kavita M., et al.
Publicado: (2002)

Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response
por: Patel, Anamika, et al.
Publicado: (2022)

Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response
por: Patel, Anamika, et al.
Publicado: (2023)

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
por: Costa, Federica, et al.
Publicado: (2018)

SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer
por: Dhodapkar, Kavita M, et al.
Publicado: (2013)

Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
por: Chang, Andres, et al.
Publicado: (2022)

BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
por: Valanparambil, Rajesh M., et al.
Publicado: (2023)

Enhancement of clonogenicity of human multiple myeloma by dendritic cells
por: Kukreja, Anjli, et al.
Publicado: (2006)

Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody
por: Kumar, Sanjeev, et al.
Publicado: (2022)

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
por: Schmidt, Timothy M., et al.
Publicado: (2019)

Natural Killer T Cells in Cancer Immunotherapy
por: Nair, Shiny, et al.
Publicado: (2017)

A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma
por: Dhodapkar, Madhav V., et al.
Publicado: (2003)

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
por: Gupta, Vikas A., et al.
Publicado: (2021)

A survey-wide association study to identify youth-specific correlates of major depressive episodes
por: Dhodapkar, Rahul Madhav
Publicado: (2020)

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer
por: Dhodapkar, Kavita, et al.
Publicado: (2014)

Tissue resident memory T cells create genetically distinct immune microenvironments within melanoma metastasis
por: Dhodapkar, Kavita, et al.
Publicado: (2015)

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
por: Barwick, Benjamin G., et al.
Publicado: (2019)

Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
por: Dhodapkar, Kavita M., et al.
Publicado: (2007)

Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
por: Dhodapkar, Kavita M., et al.
Publicado: (2007)

Venetoclax ex vivo functional profiling predicts improved progression-free survival
por: Gupta, Vikas A., et al.
Publicado: (2022)

Role of Tissue-Resident Memory in Intra-Tumor Heterogeneity and Response to Immune Checkpoint Blockade
por: Dhodapkar, Kavita M.
Publicado: (2018)

371. Estimating SARS-CoV-2 Seroprevalence from Spent Blood Samples, January–March 2021
por: Graciaa, Daniel, et al.
Publicado: (2021)

Editorial: HIV and Cancer Immunotherapy: Similar Challenges and Converging Approaches
por: Paiardini, Mirko, et al.
Publicado: (2020)

Game of Bones: How Myeloma Manipulates Its Microenvironment
por: Moser-Katz, Tyler, et al.
Publicado: (2021)

Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies
por: Chang, Andres, et al.
Publicado: (2023)

COVID-19 vaccine induced poor neutralization titers for SARS-CoV-2 omicron variants in maternal and cord blood
por: Govindaraj, Sakthivel, et al.
Publicado: (2023)

Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy
por: Dhodapkar, Madhav V., et al.
Publicado: (2003)

Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against Wuhan-WT, delta and omicron BA1, BA2 spike trimers
por: Cheedarla, Narayanaiah, et al.
Publicado: (2023)

Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against native-like vaccine and delta variant spike trimers
por: Cheedarla, Narayanaiah, et al.
Publicado: (2022)

Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells
por: Dhodapkar, Madhav V., et al.
Publicado: (2001)

Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias
por: Branagan, Andrew R., et al.
Publicado: (2021)

β-Catenin Regulates Wound Healing and IL-6 Expression in Activated Human Astrocytes
por: Edara, Venkata Viswanadh, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rnrqijt8gb7snvulkju0labtva